1. Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies

Jaleh Barar* , Yadollah Omidi*

Bioimpacts. 2015;5(2): 65-69. doi: 10.15171/bi.2015.18

PMCID: PMC4492186 PMID: 26191499 Scopus ID: 84930410369

Article

PDF

XML

Cited By:

Editorial

2. Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities

Nastran Hashemzadeh, Khosro Adibkia , Jaleh Barar*

Bioimpacts. 2019;9(1): 1-3. doi: 10.15171/bi.2019.01

PMCID: PMC6378097 PMID: 30788254 Scopus ID: 85060480524

Article

PDF

Full Text

XML

Cited By:

Review

3. CRISPR-Cas9 in basic and translational aspects of cancer therapy

Maryam Samareh Salavatipour , Zahra Poursalehi, Negin Hosseini Rouzbahani, Sohaib Mohammadyar, Mohammad Vasei*

Bioimpacts. 2024;14(6): 30087. doi: 10.34172/bi.2024.30087

PMCID: PMC11530967 PMID: 39493894 Scopus ID: 85209235663

Article

PDF

XML

Cited By:

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons